Immunogenicity and Safety of a Pneumococcal Conjugate 7-Valent Vaccine in Infants With Sickle Cell Disease

Abstract

PCV7 administered at 2, 3, and 4 months of age in infants with SCD was well-tolerated, highly immunogenic, and primed for immune memory as indicated by the dramatic response to the PS-23 dose administered at 15-18 months in this study. However, the current recommended schedule is to boost with the PCV7 at 12-15 months of age and for these high-risk children, to enlarge the protection with a subsequent PS-23 dose at 2 years of age.

Successful serology‐based intervention to increase protection against vaccine‐preventable diseases in liver‐transplanted children: A 19‐yr review of the Swiss national reference center

“…While analyzing potential determinants affecting the antibody response to vaccination, we showed that pre‐OLT titers were strongly predictive of post‐OLT titers. This was the case for all antigens except SPn23, maybe because it is the less immunogenic of the tested pneumococcal serotypes (26). Moreover, and even if this never reached significance in our cohort, patients with protective titers one yr post‐OLT had higher pre‐OLT titers than those without protective titers.…”

Impact of early transcranial Doppler screening and intensive therapy on cerebral vasculopathy outcome in a newborn sickle cell anemia cohort

“…MRI/MRA (n ϭ 463) were performed in 132 SCA patients. The median number of MRI/MRA per patient was 2 (range, [1][2][3][4][5][6][7][8]. In patients older than 5 years, MRI/MRA without sedation failed in 2 patients.…”

“…The main characteristics of the participants, grouped as SCA (n ϭ 217: 209 SS, 6 S␤ 0 , 2 SD-Punjab), are summarized in Table 1. A total of 1351 TCD were performed at annual check-ups, with a median number of TCD/patient of 6 (range, [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16]. MRI/MRA (n ϭ 463) were performed in 132 SCA patients.…”

“…[1][2][3][4][5][6][7][8]10,29,30 The mortality of 0.25/100 patient-years and survival estimate of 97.5% (95% CI 93.4%-99.1%) by age 18 years in this SCA newborn cohort (1988)(1989)(1990)(1991)(1992)(1993)(1994)(1995)(1996)(1997)(1998)(1999)(2000)(2001)(2002)(2003)(2004)(2005)(2006)(2007) seem equivalent to those of the most recently reported cohorts with 0.52 deaths/100 patient-years and 93.9% survival estimate (95% CI 90.3%-96.2%) for the Dallas cohort (1983-2007), 30 and 0.27/100 patient-years and 99.0% (95% CI 93.2%-99.9%) survival estimate by age 20 for the East London cohort . 11 The recent Dallas report also showed an improvement of survival to age 5 years since the introduction of the Prevnar vaccine in 2000.…”

“…Newborn screening, [1][2][3][4] early preventive penicillin therapy, 5 and pneumococcal vaccines have significantly reduced the incidence of early mortality. [6][7][8] Nevertheless, morbidity remains high for SCA (SS/S␤ 0 ) patients, with a reported absolute risk of 11% 9 by age 20 years for overt stroke and a cumulative stroke risk of11.5% by age 18 years 10 and 12.8% by age 20 years 11 in the most recently studied newborn-cohorts.…”